IP Library › Granted Patent US 12,419,973
Granted Patent B2
US 12,419,973 · App. 17/569,896 · Granted Sep 23, 2025

Methods and compositions for treatment of disorders and diseases involving RDH12

Inventors: Jean Bennett (Bryn Mawr, PA); Junwei Sun (Philadelphia, PA); Vidyullatha Vasireddy (Wayne, PA)
Assignee: The Trustees of the University of Pennsylvania
A61K48/0058A61K9/0019A61K9/0048A61K48/0008A61K48/005A61K48/0091A61P27/02C12N15/63C12N15/67C12Q1/68C12N2750/14143C12N2800/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,419,973
App. No.
17/569,896
Granted
Sep 23, 2025
Kind
B2
Abstract

Codon optimized nucleic acid sequences for RDH12 are provided, as well as recombinant viral vectors, such as AAV, expression cassettes, proviral plasmids or other plasmids containing the codon optimized sequence for functional RDH12. Recombinant vectors are provided that express the codon optimized, functional RDH12. Compositions containing these codon optimized sequences are useful in methods for treating, retarding or halting certain blinding diseases resulting from the absence, deficiency or inappropriate expression of RDH12. Other compositions and methods are providing for correcting a non-functional, defective or inadequately expressed native RDH12.

Claims (7)

1. A method of treating Leber Congenital Amaurosis (LCA) due to one or more loss-of function mutations in the gene encoding the retinol dehydrogenase 12 (RDH12) protein in a human subject, the method comprising administering into the subretinal space of at least one eye of the subject an adeno-associated viral (AAV) vector comprising a nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO: 5, wherein the nucleic acid is under expression control of a human rhodopsin kinase 1 (hGRK1) promoter, and wherein the nucleic acid encodes a functional RDH12 protein comprising SEQ ID NO: 2.

2. The method of claim 1 , wherein the human RDH12 DNA is codon optimized for expression in a human cell.

3. The method of claim 1 , wherein a micro injection device is inserted into the subretinal space.

4. The method of claim 1 , comprising administering the AAV vector in an amount of about 10 11 -10 13 viral particles/mL.

5. A method of treating Leber Congenital Amaurosis 13 (LCA13) due to one or more loss-of function mutations in a gene encoding a Retinol Dehydrogenase 12 (RDH12) protein in a human subject, the method comprising administering into a subretinal space of at least one eye of the human subject an adeno-associated viral (AAV) vector comprising a nucleic acid comprising the nucleotide sequence set forth in SEQ ID NO: 5, wherein the nucleic acid is under expression control of a human rhodopsin kinase 1 (hGRK1) promoter encodes a functional RDH12 protein comprising SEQ ID NO: 2.

6. The method of claim 1 , wherein the AAV vector is AAV2/5 or AAV2/8.

7. The method of claim 5 , wherein the AAV vector is AAV2/5 or AAV2/8.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2022
From: BENNETT, JEAN; SUN, JUNWEI; VASIREDDY, VIDYULLATHA
To: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Reel/Frame 058584/0391 →
Continuity (5)
Division 17523492 · Nov 10, 2021
Division 16314179
Provisional Application 62359777 · Jul 8, 2016
Related Publication 20220118111A1 · Apr 21, 2022
Related Publication 20230132391A9 · Apr 27, 2023
References Cited (121)
US 5139941A · Muzyczka et al. · 1992 [cited by applicant]
US 5478745A · Samulski et al. · 1995 [cited by applicant]
US 5741683A · Zhou et al. · 1998 [cited by applicant]
US 6057152A · Samulski et al. · 2000 [cited by applicant]
US 6204059B1 · Samulski et al. · 2001 [cited by applicant]
US 6268213B1 · Samulski et al. · 2001 [cited by applicant]
US 6491907B1 · Rabinowitz et al. · 2002 [cited by applicant]
US 6596535B1 · Carter · 2003 [cited by applicant]
US 6660514B1 · Zolotukhin et al. · 2003 [cited by applicant]
US 6951753B2 · Shenk et al. · 2005 [cited by applicant]
US 7094604B2 · Snyder et al. · 2006 [cited by applicant]
US 7125717B2 · Carter · 2006 [cited by applicant]
US 7172893B2 · Rabinowitz et al. · 2007 [cited by applicant]
US 7201898B2 · Monahan et al. · 2007 [cited by applicant]
US 7229823B2 · Samulski et al. · 2007 [cited by applicant]
US 7282199B2 · Gao · 2007 [cited by applicant]
US 7439065B2 · Ferrari et al. · 2008 [cited by applicant]
US 7456683B2 · Takano et al. · 2008 [cited by applicant]
US 7561972B1 · Welch et al. · 2009 [cited by applicant]
US 7561973B1 · Welch et al. · 2009 [cited by applicant]
US 7588772B2 · Kay et al. · 2009 [cited by applicant]
US 7629322B2 · Kleinschmidt et al. · 2009 [cited by applicant]
US 7790449B2 · Gao et al. · 2010 [cited by applicant]
US 7888112B2 · Hermanson et al. · 2011 [cited by applicant]
US 7906111B2 · Wilson et al. · 2011 [cited by applicant]
US 8147823B2 · Acland et al. · 2012 [cited by applicant]
US 9249425B2 · Bennett et al. · 2016 [cited by applicant]
US 10392622B2 · Lewis et al. · 2019 [cited by applicant]
US 11197936B2 · Bennett et al. · 2021 [cited by applicant]
US 20070036760A1 · Wilson et al. · 2007 [cited by applicant]
US 20090199733A1 · Vendenberghe et al. · 2009 [cited by applicant]
US 20100081707A1 · Ali et al. · 2010 [cited by applicant]
US 20140010861A1 · Bancel et al. · 2014 [cited by applicant]
US 20150259395A1 · Chalberg et al. · 2015 [cited by applicant]
US 20160015288A1 · Neitz et al. · 2016 [cited by applicant]
US 20190142909A1 · Thompson et al. · 2019 [cited by applicant]
EP 1310571 · 2006 [cited by applicant]
WO WO199915685 · 1999 [cited by applicant]
WO WO2003042397 · 2003 [cited by applicant]
WO WO2005033321 · 2005 [cited by applicant]
WO WO2006110689 · 2006 [cited by applicant]
WO WO2011034947A2 · 2011 [cited by examiner]
WO WO2011126808 · 2011 [cited by applicant]
WO WO2012158757 · 2012 [cited by applicant]
WO WO2013049493A1 · 2013 [cited by applicant]
WO WO2014011210 · 2014 [cited by applicant]
WO WO2015012924A2 · 2015 [cited by applicant]
WO WO2015017154 · 2015 [cited by applicant]
WO WO2016019364A1 · 2016 [cited by applicant]
WO WO2018009814A1 · 2018 [cited by applicant]
WO WO2019099696A1 · 2019 [cited by applicant]
WO WO2023129095A1 · 2023 [cited by applicant]
Khani et al. (2007, IOVS, vol. 48(9), pp. 3954-3961). (Year: 2007). [cited by examiner]
Kim et al. (1997, Gene, vol. 199, pp. 293-301). (Year: 1997). [cited by examiner]
Perrault et al. (2004, Am. J. Hum. Genet., vol. 75, pp. 639-646). (Year: 2004). [cited by examiner]
Schuster et al. (2007, Investigative Ophthalmology and Visual Science, vol. 48(4), pp. 1824-18311). (Year: 2007). [cited by examiner]
2008, Retinal Health Series-Leber Congenital Amaurosis, 2 pages (Year: 2008). [cited by examiner]
Albakri, A et al., Elevation Deficiency in Children with Recessive RDH12-Related Retinopathy. Journal of AAPOS. Dec. 2015; vol. 19, No. 6; pp. 568-570. [cited by applicant]
Beltran et al., rAAV2/5 gene-targeting to rods: dose-dependent efficiency and complications associated with different promotersGene Therapy, Sep. 2010, 17(9):1162-74. [cited by applicant]
Buie et al., Jan. 2010, Self-complementary AAV Virus (scAAV) Safe and Long- term Gene Transfer in the Trabecular Meshwork of Living Rats and Monkeys, Invest Ophthalmol Vis Sci., 51(1): 236-248. [cited by applicant]
Buning et al., 2008, Recent developments in adeno-associated virus vector technology, J. Gene Med. 10:717-733. [cited by applicant]
Cai, X et al., A 350 bp region of the proximal promoter of Rds drives cell-type specific gene expression., Exp Eye Res. Aug. 2010: 91(2):186-194. [cited by applicant]
Cong, L., et al. Multiplex genome engineering using CRISPR/Cas systems. Science. Feb. 15, 2013;339(6121):819-23. doi: 10.1126/science.1231143. (Epub Jan. 3, 2013). [cited by applicant]
Dalkara et al., In Vivo—Directed Evolution of a New Adeno-Associated Virus for Therapeutic Outer Retinal Gene Delivery from the Vitreous, Sci Transl Med 5, 189ra76 (Jun. 2013). [cited by applicant]
Damdindorj et al., (Aug. 2014) A Comparative Analysis of Constitutive Promoters Located in Adeno-Associated Viral Vectors. PLoS One 9(8): e106472. [cited by applicant]
Diehl, K-H et al., A Good Practice Guide to the Administration of Substances and Removal of Blood, Including Routes and vols. J. Applied Toxicology, 21:15-23 (Sep. 2001). [cited by applicant]
Fingert et al., Association of a novel mutation in the retinol dehydrogenase 12 (RDH12) gene with autosomal dominant retinitis pigmentosa, Arch Ophthalmol. Sep. 2008;126(9):1301-7. [cited by applicant]
Fisher et al., Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis, Journal of Virology, vol. 70(1):520-532, Jan. 1996. [cited by applicant]
Grieger, MC & Samulski, RJ, 2005, Adeno-associated virus as a gene therapy vector: Vector development, production and clinical applications, Adv. Biochem. Engin/Biotechnol. 99: 119-145. [cited by applicant]
Hamilton, MM et al., Repeated Administration of Adenovector in the Eye Results in Efficient Gene Delivery. Investigative Ophthalmology and Visual Sciences. Jan. 2006; vol. 47, No. 1; pp. 299-305. [cited by applicant]
Kachi et al., Equine Infectious Anemia Viral Vector-Mediated Codelivery of Endostatin and Angiostatin Driven by Retinal Pigmented Epithelium-Specific VMD2 Promoter Inhibits Choroidal Neovascularization, Human Gene Thera… [cited by applicant]
Kasus-Jacobi et al., Mechanisms of RDH12-Induced Leber Congenital Amaurosis and Therapeutic Approaches, In Advances in Opthamology, Dr. Shimon Rumelt (Ed.), pp. 473-496, 2012. [cited by applicant]
Kay et al., Apr. 2013, Targeting Photoreceptors via Intravitreal Delivery Using Novel, Capsid-Mutated AAV Vectors, PLoS One. 2013; 8(4): e62097. [cited by applicant]
Kim, Novel Approaches for Retinal Drug and Gene Delivery, Transl Vis Sci Technol. Oct. 3, 2014;3(5):7. doi: 10.1167/tvst.3.5.7. eCollection Sep. 2014. [cited by applicant]
Kozak et al., An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs, Nucleic Acids Res., vol. 15(20): 8125-8148, Oct. 1987. [cited by applicant]
Kroptova et al., Expression of genes involved in retinoic acid biosynthesis in human gastric cancer, Molecular Biology, 47(2): 280-292, 2012. [cited by applicant]
Ku et al., Dec. 2011, Gene therapy using self-complementary Y733F capsid mutant AAV2/8 restores vision in a model of early onset Leber congenital amaurosis, Hum Mol Genet., 20(23): 4569-4581. [cited by applicant]
Lambard et al., Expression of Rod-Derived Cone Viability Factor: Dual Role of CRX in Regulating Promoter Activity and Cell-Type Specificity, PLoS One, vol. 5(10):e13025, Oct. 2010. [cited by applicant]
Lee, Sa et al., Overproduction of Bioactive Retinoic Acid in Celts Expressing Disease—associated Mutants of Retinol Dehydrogenase 12. Journal of Biological Chemistry. Oct. 9, 2009; vol. 282, No. 49; pp. 35621-35628. [cited by applicant]
Lock M, et al., Absolute determination of single-stranded and self-complementary adeno-associated viral vector genome titers by droplet digital PCR. Hum Gene Ther Methods. Apr. 2014;25(2):115-25. doi: 10.1089/hgtb.2013.… [cited by applicant]
Mackay, DS et al., RDH12 Retinopathy: Novel Mutations and Phenotypic Description. Molecular Vision. Oct. 19, 2011; vol. 17; pp. 2706-2716. [cited by applicant]
Mali, P, et al. RNA-guided human genome engineering via Cas9. Science. Feb. 15, 2013;339(6121):823-6. doi: 10.1126/science.1232033. (Epub Jan. 3, 2013). [cited by applicant]
McCarty, DM et al., Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis, Gene Therapy, (Aug. 2001), vol. 8, No. 16, pp. 1248-1254. [cited by applicant]
McLaughlin et al., Adeno-Associated Virus General Transduction Vectors: Analysis of Proviral Structures, J. Virol., vol. 62:1963, Jun. 1988. [cited by applicant]
Meindl et al., A gene (RPGR) with homology to the RCC1 guanine nucleotide exchange factor is mutated in X-linked retinitis pigmentosa (RP3), Nat Genet, vol. 13:35-42, May 1996. [cited by applicant]
Morrissey et al., PRE-1, a cis element sufficient to enhance cone-and-rod-specific expression in differentiating zebrafish photoreceptors, BMC Dev, Biol, vol. 11:3, Jan. 2011. [cited by applicant]
Mowat et al., Jan. 2014, Tyrosine capsid-mutant AAV vectors for gene delivery to the canine retina from a subretinal or intravitreal approach, Gene Therapy 21, 96-105. [cited by applicant]
Mussolino et al., AAV-mediated photoreceptor transduction of the pig cone-enriched retina, Gene Ther, vol. 18(7):637-45, Jul. 2011. [cited by applicant]
Nicoud et al., Development of photoreceptor-specific promoters and their utility to investigate EIAV lentiviral vector mediated gene transfer to photoreceptors, J. Gene Med, vol. 9(12):1015-23, Dec. 2007. [cited by applicant]
Qiao et al., A Novel RNA-Seq-Based Model for Preoperative Prediction of Lymph Node Metastasis in Oral Squamous Cell Carcinoma, Biomed Res Int. Aug. 31, 2020;2020:4252580. [cited by applicant]
Ran FA, et al., Genome engineering using the CRISPR-Cas9 system. Nat Protoc. Nov. 2013;8(11):2281-2308. doi: 10.1038/nprot.2013.143. (Epub Oct. 24, 2013). [cited by applicant]
Rowe-Rendleman, et al. Drug and gene delivery to the back of the eye: from bench to bedside, Invest Ophthalmol Vis Sci. Apr. 28, 2014;55(4):2714-30. [cited by applicant]
Ryals et al., Apr. 2011, Quantifying transduction efficiencies of unmodified and tyrosine capsid mutant AAV vectors in vitro using two ocular cell lines, Mol Vis.; 17:1090-102. [cited by applicant]
Sarkar et al., Novel Heterozygous Deletion in Retinol Dehydrogenase 12 (RDH12) Causes Familial Autosomal Dominant Retinitis Pigmentosa, Front Genet. Apr. 8, 2020;11:335. [cited by applicant]
Sarkar et al., Retinol dehydrogenase 12 (RDH12): Role in vision, retinal disease and future perspectives, Exp Eye Res. Nov. 2019;188:107793. Epub Sep. 7, 2019. [cited by applicant]
Shalem, O et al., Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells. Science, Jan. 2014., 343(6166):84-87. [cited by applicant]
Shu, X et al., Functional Characterization of the Human RPGR Proximal Promoter., Invest. Ophthalmol. Vis. Sci., May 2012; 53:3951-3958. [cited by applicant]
Sofia et al., Report from a Workshop on Accelerating the Development of Treatments for Inherited Retinal Dystrophies Associated with Mutations in the RDH12 Gene, Transl Vis Sci Technol. Jul. 17, 2020;9(8):30. [cited by applicant]
Thompson et al., AAV-mediated Expression of Human Rdh12 in Mouse Retina, ARVO Annual Meeting Abstract, Investigative Ophthalmology & Visual Science, vol. 53(1916), Mar. 2012. [cited by applicant]
Thompson, DA et al., Retinal degeneration associated with RDH12 mutations results from decreased 11-cis retinal synthesis due to disruption of the visual cycle. Human Mol. Genet., 14(24):3865-3875, Nov. 2005. [cited by applicant]
Thomson, JD et al., Nucl. Acids. Res., A comprehensive comparison of multiple sequence alignments, 27(13):2682-2690 (1999). [cited by applicant]
Tuohy et al., A report on a workshop for accelerating the development of treatments for inherited retinal degenerations (IRDs), Sep. 2020, (retrieved from https://brief.euretina.org/research/a-report-on-a-workshop-for-a… [cited by applicant]
Vervoort et al., Mutational hot spot within a new RPGR exon in X-linked retinitis pigmentosa, Nat Genet, vol. 25(4):462-466, Aug. 2000. [cited by applicant]
Vervoort et al., Mutations of RPGR in X-linked Retinitis Pigmentosa (RP3), Human Mutation, vol. 19:486-500, Apr. 2002. [cited by applicant]
Wang et al., Sustained correction of bleeding disorder in hemophilia B mice by gene therapy, Proc. Natl. Acad. Sci., USA, vol. 96(7):3906-3910, Mar. 1999. [cited by applicant]
Yin H, et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol. Jun. 2014;32(6):551-3. doi: 10.1038/nbt.2884. (Epub Mar. 30, 2014). [cited by applicant]
Zhang H, et al., Adenovirus-adeno-associated virus hybrid for large-scale recombinant adeno-associated virus production. Hum Gene Ther. Sep. 2009;20(9):922-9. doi: 10.1089/hum.2009.125. (Online Ahead of Editing: Jul. 20… [cited by applicant]
International Search Report dated Oct. 2, 2017 in corresponding International Patent Application PCT/US17/41122, filed Jul. 7, 2017. [cited by applicant]
Written Opinion dated Oct. 2, 2017 in corresponding International Patent Application PCT/US17/41122, filed Jul. 7, 2017. [cited by applicant]
Office Action issued in corresponding Japanese Patent Application No. 2019-500531, dated Jun. 9, 2021, with translation provided by local agent. [cited by applicant]
Extended European Search Report issued in European Patent Application No. 17824989.2, dated Nov. 27, 2019. [cited by applicant]
Restriction Requirement issued in U.S. Appl. No. 16/314,178, dated May 1, 2020. [cited by applicant]
Applicant's Response and Amendment in U.S. Appl. No. 16/314,178, filed Jul. 1, 2020. [cited by applicant]
Office Action issued in U.S. Appl. No. 16/314,178, dated Oct. 6, 2020. [cited by applicant]
Applicant's Response and Amendment in U.S. Appl. No. 16/314,178, filed Jan. 6, 2021. [cited by applicant]
Office Action issued in U.S. Appl. No. 16/314,178, dated Apr. 20, 2021. [cited by applicant]
Applicant's Response and Amendment in U.S. Appl. No. 16/314,178, filed Jul. 19, 2021. [cited by applicant]
Notice of Allowance issued in U.S. Appl. No. 16/314,178, dated Aug. 11, 2021. [cited by applicant]
Samulski, R Jude, and Muzyczka, N., AAV-Mediated Gene Therapy for Research and Therapeutic Purposes. Annu Rev Virol. Nov. 2014;1(1):427-51. [cited by applicant]
Non-Final Office Action dated Nov. 20, 2023 issued in U.S. Appl. No. 17/822,533, and Response filed Jan. 31, 2024. [cited by applicant]
Final Office Action dated Feb. 28, 2024 issued in U.S. Appl. No. 17/822,533, and Response filed Apr. 26, 2024. [cited by applicant]